

**Clinical trial results:****A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Osteosarcoma or Ewing's Sarcoma That Has Relapsed After Standard Systemic Therapy**

The data reported in v3 is not correct and has been removed from public view

Summary

EudraCT number	2007-005341-38
Trial protocol	DE FR ES SE NO NL IT CZ PT HU GB
Global end of trial date	31 August 2013

Results information

Result version number	v4 (current)
This version publication date	30 April 2016
First version publication date	13 June 2015
Version creation reason	

Trial information**Trial identification**

Sponsor protocol code	P04720
-----------------------	--------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00617890
WHO universal trial number (UTN)	-
Other trial identifiers	MK-7454-002: Merck study number

Notes:

Sponsors

Sponsor organisation name	Merck Sharp & Dohme Corp.
Sponsor organisation address	2000 Galloping Hill Road, Kenilworth, NJ, United States, 07033
Public contact	Clinical Trials Disclosure, Merck Sharp & Dohme Corp., ClinicalTrialsDisclosure@merck.com
Scientific contact	Clinical Trials Disclosure, Merck Sharp & Dohme Corp., ClinicalTrialsDisclosure@merck.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	31 August 2013
Is this the analysis of the primary completion data?	Yes
Primary completion date	31 August 2011
Global end of trial reached?	Yes
Global end of trial date	31 August 2013
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

Group 1-Determine tumor cell proliferation response after dosing with SCH 717454 in subjects with resectable osteosarcoma that has relapsed after standard systemic therapy compared to the subject's historical tumor cell proliferation. Group 2-Determine the World Health Organization (WHO) and Response Evaluation Criteria in Solid Tumors (RECIST)-defined radiological response rate to SCH 717454 in subjects with unresectable osteosarcoma refractory to standard therapy. Group 3-Determine the WHO and RECIST-defined radiological response rate to SCH 717454 in subjects with Ewing's sarcoma refractory to standard therapy. The study was prematurely terminated for strategic reasons, not for a safety concern; analyses of some efficacy endpoints were not performed due to large number of incomplete or uncleaned data which occurred as a result of the early termination. Participants could continue on drug per usual standard of care as long as receiving clinical benefit per Investigator discretion.

Protection of trial subjects:

This study was conducted in conformance with Good Clinical Practice standards and applicable country and/or local statutes and regulations regarding ethical committee review, informed consent, and the protection of human subjects participating in biomedical research.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	01 February 2008
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Canada: 8
Country: Number of subjects enrolled	Brazil: 10
Country: Number of subjects enrolled	Chile: 4
Country: Number of subjects enrolled	Mexico: 2
Country: Number of subjects enrolled	Peru: 3
Country: Number of subjects enrolled	Taiwan: 12
Country: Number of subjects enrolled	Turkey: 1
Country: Number of subjects enrolled	United States: 115
Country: Number of subjects enrolled	Argentina: 1
Country: Number of subjects enrolled	Australia: 1
Country: Number of subjects enrolled	Guatemala: 2
Country: Number of subjects enrolled	Korea, Republic of: 3
Country: Number of subjects enrolled	Netherlands: 5
Country: Number of subjects enrolled	Norway: 3

Country: Number of subjects enrolled	Spain: 3
Country: Number of subjects enrolled	Sweden: 2
Country: Number of subjects enrolled	United Kingdom: 3
Country: Number of subjects enrolled	France: 22
Country: Number of subjects enrolled	Germany: 12
Country: Number of subjects enrolled	Hungary: 4
Country: Number of subjects enrolled	Italy: 3
Worldwide total number of subjects	219
EEA total number of subjects	57

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	14
Adolescents (12-17 years)	56
Adults (18-64 years)	147
From 65 to 84 years	2
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

This study enrolled both adult and child participants with relapsed resectable osteosarcoma after definitive treatment, participants with relapsed unresectable osteosarcoma refractory to prior chemotherapy, and participants with Ewing's sarcoma refractory to prior treatment.

Pre-assignment

Screening details:

Participants were to have a minimum life expectancy of ≥ 8 weeks.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Blinding implementation details:

Group 1 participants were given randomized assignment to a dose of 0.3 mg/kg or 10 mg/kg of robatumumab; Group 1 was blinded (investigator and participant) but not controlled.

Arms

Are arms mutually exclusive?	Yes
Arm title	Group 1: 0.3 mg/kg

Arm description:

Participants received robatumumab 0.3 mg/kg intravenously (IV) as a single dose on Day 1, followed by surgery on Day 10 to 14, and four weeks later, resumption of robatumumab 0.3 mg/kg on the same calendar day (± 3 days) once every 2 weeks until disease recurrence or up to 1 year of dosing. This group comprised participants with resectable osteosarcoma that relapsed within 6 months of prior definitive treatment (eg surgical metastasectomy) and having at least one prior chemotherapy regimen containing a platinum agent and doxorubicin.

Arm type	Experimental
Investigational medicinal product name	robatumumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for injection
Routes of administration	Intravenous use

Dosage and administration details:

Robatumumab was supplied as a concentrated solution for infusion.

Arm title	Group 1: 10 mg/kg
------------------	-------------------

Arm description:

Participants received robatumumab 10 mg/kg IV as a single dose on Day 1, followed by surgery on Day 10 to 14, and four weeks later, resumption of robatumumab 10 mg/kg on the same calendar day (± 3 days) once every 2 weeks until disease recurrence or up to 1 year of dosing. This group comprised participants with resectable osteosarcoma that relapsed within 6 months of prior definitive treatment (eg surgical metastasectomy) and having at least one prior chemotherapy regimen containing a platinum agent and doxorubicin.

Arm type	Experimental
Investigational medicinal product name	robatumumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for injection
Routes of administration	Intravenous use

Dosage and administration details:

Robatumumab was supplied as a concentrated solution for infusion.

Arm title	Group 2: 10 mg/kg
Arm description:	
Participants received robatumumab 10 mg/kg IV biweekly until disease recurrence or up to 1 year of dosing. This group comprised participants with relapsed and unresectable osteosarcoma refractory to prior chemotherapy with a platinum- and doxorubicin-containing regimen.	
Arm type	Experimental
Investigational medicinal product name	robatumumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for injection
Routes of administration	Intravenous use

Dosage and administration details:

Robatumumab was supplied as a concentrated solution for infusion.

Arm title	Group 3: 10 mg/kg
Arm description:	
Participants received robatumumab 10 mg/kg IV biweekly until disease recurrence or up to 1 year of dosing. This group comprised participants with Ewing's sarcoma refractory to prior treatment with at least 3 of the following agents: ifosfamide, etoposide, cyclophosphamide, doxorubicin, or vincristine.	
Arm type	Experimental
Investigational medicinal product name	robatumumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for injection
Routes of administration	Intravenous use

Dosage and administration details:

Robatumumab was supplied as a concentrated solution for infusion.

Number of subjects in period 1	Group 1: 0.3 mg/kg	Group 1: 10 mg/kg	Group 2: 10 mg/kg
Started	35	33	35
Received treatment	34	33	34
Completed	4	5	0
Not completed	31	28	35
Consent withdrawn by subject	4	1	-
Treatment ongoing at data cut-off	-	-	-
Adverse event, non-fatal	1	-	3
Lost to follow-up	-	-	1
Not treated	1	-	1
Protocol deviation	2	1	-
Lack of efficacy	23	26	30

Number of subjects in period 1	Group 3: 10 mg/kg
Started	116
Received treatment	115
Completed	1
Not completed	115

Consent withdrawn by subject	2
Treatment ongoing at data cut-off	5
Adverse event, non-fatal	8
Lost to follow-up	2
Not treated	1
Protocol deviation	-
Lack of efficacy	97

Baseline characteristics

Reporting groups

Reporting group title	Group 1: 0.3 mg/kg
Reporting group description:	
Participants received robatumumab 0.3 mg/kg intravenously (IV) as a single dose on Day 1, followed by surgery on Day 10 to 14, and four weeks later, resumption of robatumumab 0.3 mg/kg on the same calendar day (\pm 3 days) once every 2 weeks until disease recurrence or up to 1 year of dosing. This group comprised participants with resectable osteosarcoma that relapsed within 6 months of prior definitive treatment (eg surgical metastasectomy) and having at least one prior chemotherapy regimen containing a platinum agent and doxorubicin.	
Reporting group title	Group 1: 10 mg/kg
Reporting group description:	
Participants received robatumumab 10 mg/kg IV as a single dose on Day 1, followed by surgery on Day 10 to 14, and four weeks later, resumption of robatumumab 10 mg/kg on the same calendar day (\pm 3 days) once every 2 weeks until disease recurrence or up to 1 year of dosing. This group comprised participants with resectable osteosarcoma that relapsed within 6 months of prior definitive treatment (eg surgical metastasectomy) and having at least one prior chemotherapy regimen containing a platinum agent and doxorubicin.	
Reporting group title	Group 2: 10 mg/kg
Reporting group description:	
Participants received robatumumab 10 mg/kg IV biweekly until disease recurrence or up to 1 year of dosing. This group comprised participants with relapsed and unresectable osteosarcoma refractory to prior chemotherapy with a platinum- and doxorubicin-containing regimen.	
Reporting group title	Group 3: 10 mg/kg
Reporting group description:	
Participants received robatumumab 10 mg/kg IV biweekly until disease recurrence or up to 1 year of dosing. This group comprised participants with Ewing's sarcoma refractory to prior treatment with at least 3 of the following agents: ifosfamide, etoposide, cyclophosphamide, doxorubicin, or vincristine.	

Reporting group values	Group 1: 0.3 mg/kg	Group 1: 10 mg/kg	Group 2: 10 mg/kg
Number of subjects	35	33	35
Age categorical			
Units: Subjects			

Age continuous			
Units: years			
arithmetic mean	23.7	20.1	27.5
standard deviation	\pm 15.5	\pm 10.3	\pm 15.3
Gender categorical			
Units: Subjects			
Female	14	13	11
Male	21	20	24

Reporting group values	Group 3: 10 mg/kg	Total	
Number of subjects	116	219	
Age categorical			
Units: Subjects			

Age continuous			
Units: years			
arithmetic mean	24.6		

standard deviation	± 11.4	-	
--------------------	--------	---	--

Gender categorical Units: Subjects			
Female	43	81	
Male	73	138	

End points

End points reporting groups

Reporting group title	Group 1: 0.3 mg/kg
Reporting group description: Participants received robatumumab 0.3 mg/kg intravenously (IV) as a single dose on Day 1, followed by surgery on Day 10 to 14, and four weeks later, resumption of robatumumab 0.3 mg/kg on the same calendar day (\pm 3 days) once every 2 weeks until disease recurrence or up to 1 year of dosing. This group comprised participants with resectable osteosarcoma that relapsed within 6 months of prior definitive treatment (eg surgical metastasectomy) and having at least one prior chemotherapy regimen containing a platinum agent and doxorubicin.	
Reporting group title	Group 1: 10 mg/kg
Reporting group description: Participants received robatumumab 10 mg/kg IV as a single dose on Day 1, followed by surgery on Day 10 to 14, and four weeks later, resumption of robatumumab 10 mg/kg on the same calendar day (\pm 3 days) once every 2 weeks until disease recurrence or up to 1 year of dosing. This group comprised participants with resectable osteosarcoma that relapsed within 6 months of prior definitive treatment (eg surgical metastasectomy) and having at least one prior chemotherapy regimen containing a platinum agent and doxorubicin.	
Reporting group title	Group 2: 10 mg/kg
Reporting group description: Participants received robatumumab 10 mg/kg IV biweekly until disease recurrence or up to 1 year of dosing. This group comprised participants with relapsed and unresectable osteosarcoma refractory to prior chemotherapy with a platinum- and doxorubicin-containing regimen.	
Reporting group title	Group 3: 10 mg/kg
Reporting group description: Participants received robatumumab 10 mg/kg IV biweekly until disease recurrence or up to 1 year of dosing. This group comprised participants with Ewing's sarcoma refractory to prior treatment with at least 3 of the following agents: ifosfamide, etoposide, cyclophosphamide, doxorubicin, or vincristine.	

Primary: Number of Participants Achieving a Complete Response or Partial Response (Group 3 Only)

End point title	Number of Participants Achieving a Complete Response or Partial Response (Group 3 Only) ^{[1][2]}
End point description: This is a measure of the number of participants with a complete response (CR) or partial response (PR) to therapy, confirmed by central review. Response was based on Response Evaluation Criteria in Solid Tumors (RECIST) and World Health Organization (WHO) criteria.	
End point type	Primary
End point timeframe: Up to 1 year following the start of study therapy	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis was done for this endpoint due to early termination.

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This analysis was only planned for Group 3 participants.

End point values	Group 3: 10 mg/kg			
Subject group type	Reporting group			
Number of subjects analysed	84 ^[3]			
Units: Participants	6			

Notes:

[3] - Participants with evaluable data

Statistical analyses

No statistical analyses for this end point

Primary: Number of Participants Achieving a Complete Response, a Partial Response, or Stable Disease (Group 2 Only)

End point title	Number of Participants Achieving a Complete Response, a Partial Response, or Stable Disease (Group 2 Only) ^{[4][5]}
-----------------	--

End point description:

Responses to treatment (complete response, partial response, or stable disease) confirmed by central review for participants in Group 2. Response was based on Response Evaluation Criteria in Solid Tumors (RECIST) and World Health Organization (WHO) criteria.

End point type	Primary
----------------	---------

End point timeframe:

Up to 1 year following the start of study therapy

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis was done for this endpoint due to early termination.

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This analysis was only planned for Group 2 participants.

End point values	Group 2: 10 mg/kg			
Subject group type	Reporting group			
Number of subjects analysed	29 ^[6]			
Units: Participants	6			

Notes:

[6] - Accrual to this arm was stopped due to no responses.

Statistical analyses

No statistical analyses for this end point

Primary: Number of Participants With $\geq 25\%$ Change in Tumor Proliferation After Exposure to Robatumumab (Group 1 Only)

End point title	Number of Participants With $\geq 25\%$ Change in Tumor Proliferation After Exposure to Robatumumab (Group 1 Only) ^{[7][8]}
-----------------	--

End point description:

Tumor proliferation was measured using Ki-67 levels. Ki-67 is nuclear protein associated with cellular proliferation.

End point type	Primary
----------------	---------

End point timeframe:

Approximately 14 days

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This endpoint could not be analysed due to early study termination.

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This analysis was only planned for Group 1 participants.

End point values	Group 1: 0.3 mg/kg	Group 1: 10 mg/kg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[9]	0 ^[10]		
Units: Participants				

Notes:

[9] - This endpoint was not evaluated due to early termination of the study.

[10] - This endpoint was not evaluated due to early termination of the study.

Statistical analyses

No statistical analyses for this end point

Secondary: Overall Survival

End point title	Overall Survival
End point description: The endpoint is defined as the number of participants known to be alive at the time of data analysis for the study.	
End point type	Secondary
End point timeframe: From start of treatment until death or data analysis cut off (Up to 3.4 years)	

End point values	Group 1: 0.3 mg/kg	Group 1: 10 mg/kg	Group 2: 10 mg/kg	Group 3: 10 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	35	33	35	116
Units: Participants	17	16	7	28

Statistical analyses

No statistical analyses for this end point

Secondary: Time Until Tumor Relapse (Group 1 Only)

End point title	Time Until Tumor Relapse (Group 1 Only) ^[11]
End point description: This is a measure of the time from the start of the study to documented relapse of disease (up to 3.4 years).	
End point type	Secondary
End point timeframe: From start of treatment until relapse or data analysis cut off (Up to 3.4 years)	

Notes:

[11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This analysis was only planned for Group 1 participants.

End point values	Group 1: 0.3 mg/kg	Group 1: 10 mg/kg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[12]	0 ^[13]		
Units: months				
median (confidence interval 95%)	(to)	(to)		

Notes:

[12] - This endpoint was not evaluated due to early termination of the study

[13] - This endpoint was not evaluated due to early termination of the study

Statistical analyses

No statistical analyses for this end point

Secondary: Area Under the Concentration-time Curve (AUC) of Serum Levels of Robatumumab (Group 1 Only)

End point title	Area Under the Concentration-time Curve (AUC) of Serum Levels of Robatumumab (Group 1 Only) ^[14]
-----------------	---

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

End of infusion on Day 1, and then prior to surgery, before and after the 2nd, 3rd, and 8th doses (up to 20 weeks)

Notes:

[14] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This analysis was only planned for Group 1 participants.

End point values	Group 1: 0.3 mg/kg	Group 1: 10 mg/kg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[15]	0 ^[16]		
Units: µg*day/mL				
geometric mean (geometric coefficient of variation)	()	()		

Notes:

[15] - This endpoint was not evaluated due to early termination of the study

[16] - This endpoint was not evaluated due to early termination of the study

Statistical analyses

No statistical analyses for this end point

Secondary: Incidence of Anti-robotumumab Antibodies

End point title	Incidence of Anti-robotumumab Antibodies
-----------------	--

End point description:

For biological agents, it is possible for the host (participant) to develop antibodies to the agent. This

endpoint was planned to find out the number of participants who developed the antibodies after treatment with robatumumab.

End point type	Secondary
End point timeframe:	
Up to 2 years	

End point values	Group 1: 0.3 mg/kg	Group 1: 10 mg/kg	Group 2: 10 mg/kg	Group 3: 10 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[17]	0 ^[18]	0 ^[19]	0 ^[20]
Units: Percent of Participants				

Notes:

[17] - This endpoint was not evaluated due to early termination of the study

[18] - This endpoint was not evaluated due to early termination of the study

[19] - This endpoint was not evaluated due to early termination of the study

[20] - This endpoint was not evaluated due to early termination of the study

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants Experiencing Treatment-Emergent Adverse Events

End point title	Number of Participants Experiencing Treatment-Emergent Adverse Events
-----------------	---

End point description:

An adverse event is any unfavorable and unintended change in the structure, function, or chemistry of the body whether or not considered related to the study treatment. Treatment-emergent adverse events are those that occur after participants have received study treatment, or existing adverse events that occurred during screening that increase in severity after study treatment. Adverse events in the Group 1: 0.3 mg/kg arm that occurred after switching to the 10 mg/kg dose are displayed under the originally assigned treatment.

End point type	Secondary
End point timeframe:	
Up to 2 years	

End point values	Group 1: 0.3 mg/kg	Group 1: 10 mg/kg	Group 2: 10 mg/kg	Group 3: 10 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	34	33	34	115
Units: Participants	31	30	31	112

Statistical analyses

No statistical analyses for this end point

Secondary: Time to Disease Progression (Groups 2 and 3 Only)

End point title	Time to Disease Progression (Groups 2 and 3 Only) ^[21]
-----------------	---

End point description:

This is a measure of the time from the start of the study to the time of documented disease progression.

End point type	Secondary
----------------	-----------

End point timeframe:

From the start of treatment until disease progression or data analysis cut off (Up to 3.4 years)

Notes:

[21] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This analysis was only planned for Group 2 and 3 participants.

End point values	Group 2: 10 mg/kg	Group 3: 10 mg/kg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[22]	0 ^[23]		
Units: months				
median (confidence interval 95%)	(to)	(to)		

Notes:

[22] - This endpoint was not evaluated due to early termination of the study

[23] - This endpoint was not evaluated due to early termination of the study

Statistical analyses

No statistical analyses for this end point

Secondary: Duration of Response (Groups 2 and 3 Only)

End point title	Duration of Response (Groups 2 and 3 Only) ^[24]
-----------------	--

End point description:

This is a measure of the amount of time in which the tumor responded to therapy.

End point type	Secondary
----------------	-----------

End point timeframe:

From time of documented response until disease progression or data analysis cut off (Up to 3.4 years)

Notes:

[24] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This analysis was only planned for Group 2 and 3 participants.

End point values	Group 2: 10 mg/kg	Group 3: 10 mg/kg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[25]	0 ^[26]		
Units: months				
median (confidence interval 95%)	(to)	(to)		

Notes:

[25] - This endpoint was not evaluated due to early termination of the study

[26] - This endpoint was not evaluated due to early termination of the study

Statistical analyses

No statistical analyses for this end point

Secondary: Overall Survival (Groups 2 and 3 Only)

End point title	Overall Survival (Groups 2 and 3 Only) ^[27]
-----------------	--

End point description:

This is a measure of the time of survival from first dose to documentation of death

End point type	Secondary
----------------	-----------

End point timeframe:

From start of treatment until death or data analysis cut off (Up to 3.4 years)

Notes:

[27] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This analysis was only planned for Group 2 and 3 participants.

End point values	Group 2: 10 mg/kg	Group 3: 10 mg/kg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	35	116		
Units: months				
median (confidence interval 95%)	8.18 (2.96 to 10.58)	6.93 (4.93 to 11.1)		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Adverse events are reported from enrollment up to 5 weeks after the end of treatment (up to 2 years).

Adverse event reporting additional description:

All treated participants; adverse events in the Group 1: 0.3 mg/kg arm that occurred after switching to the 10 mg/kg dose are displayed under the originally assigned treatment.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	14.0
--------------------	------

Reporting groups

Reporting group title	Group 1: 0.3mg/kg
-----------------------	-------------------

Reporting group description:

Participants received robatumumab 0.3 mg/kg intravenously (IV) as a single dose on Day 1, followed by surgery on Day 10 to 14, and four weeks later, resumption of robatumumab 0.3 mg/kg on the same calendar day (\pm 3 days) once every 2 weeks until disease recurrence or up to 1 year of dosing. This group comprised participants with resectable osteosarcoma that relapsed within 6 months of prior definitive treatment (eg surgical metastasectomy) and having at least one prior chemotherapy regimen containing a platinum agent and doxorubicin.

Reporting group title	Group 2: 10mg/kg
-----------------------	------------------

Reporting group description:

Participants received robatumumab 10 mg/kg IV biweekly until disease recurrence or up to 1 year of dosing. This group comprised participants with relapsed and unresectable osteosarcoma refractory to prior chemotherapy with a platinum- and doxorubicin-containing regimen.

Reporting group title	Group 3: 10mg/kg
-----------------------	------------------

Reporting group description:

Participants received robatumumab 10 mg/kg IV biweekly until disease recurrence or up to 1 year of dosing. This group comprised participants with Ewing's sarcoma refractory to prior treatment with at least 3 of the following agents: ifosfamide, etoposide, cyclophosphamide, doxorubicin, or vincristine.

Reporting group title	Group 1: 10mg/kg
-----------------------	------------------

Reporting group description:

Participants received robatumumab 10 mg/kg IV as a single dose on Day 1, followed by surgery on Day 10 to 14, and four weeks later, resumption of robatumumab 10 mg/kg on the same calendar day (\pm 3 days) once every 2 weeks until disease recurrence or up to 1 year of dosing. This group comprised participants with resectable osteosarcoma that relapsed within 6 months of prior definitive treatment (eg surgical metastasectomy) and having at least one prior chemotherapy regimen containing a platinum agent and doxorubicin.

Serious adverse events	Group 1: 0.3mg/kg	Group 2: 10mg/kg	Group 3: 10mg/kg
Total subjects affected by serious adverse events			
subjects affected / exposed	17 / 34 (50.00%)	12 / 34 (35.29%)	57 / 115 (49.57%)
number of deaths (all causes)	6	1	14
number of deaths resulting from adverse events	1	0	1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cancer Pain			

subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant Pleural Effusion			
subjects affected / exposed	0 / 34 (0.00%)	1 / 34 (2.94%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteosarcoma Recurrent			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastases To Lung			
subjects affected / exposed	1 / 34 (2.94%)	0 / 34 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Tumour Pain			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	3 / 115 (2.61%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Hypotension			
subjects affected / exposed	1 / 34 (2.94%)	0 / 34 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhage			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Shock Haemorrhagic			
subjects affected / exposed	1 / 34 (2.94%)	0 / 34 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	1 / 1	0 / 0	0 / 0
Surgical and medical procedures			

Leg Amputation			
subjects affected / exposed	1 / 34 (2.94%)	0 / 34 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Medical Device Removal			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound Treatment			
subjects affected / exposed	1 / 34 (2.94%)	0 / 34 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thoracotomy			
subjects affected / exposed	1 / 34 (2.94%)	0 / 34 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest Pain			
subjects affected / exposed	0 / 34 (0.00%)	1 / 34 (2.94%)	4 / 115 (3.48%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device Dislocation			
subjects affected / exposed	1 / 34 (2.94%)	0 / 34 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Condition Aggravated			
subjects affected / exposed	1 / 34 (2.94%)	0 / 34 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Fatigue			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug Withdrawal Syndrome			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperthermia			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General Physical Health Deterioration			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza Like Illness			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malaise			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mucosal Inflammation			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multi-Organ Failure			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Oedema Peripheral			

subjects affected / exposed	1 / 34 (2.94%)	0 / 34 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	11 / 115 (9.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 13
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Performance Status Decreased			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	1 / 34 (2.94%)	0 / 34 (0.00%)	7 / 115 (6.09%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 11
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Acute respiratory distress syndrome			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute Respiratory Failure			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	2 / 115 (1.74%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 2
Bronchial Disorder			
subjects affected / exposed	1 / 34 (2.94%)	0 / 34 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea At Rest			
subjects affected / exposed	0 / 34 (0.00%)	1 / 34 (2.94%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			

subjects affected / exposed	0 / 34 (0.00%)	2 / 34 (5.88%)	3 / 115 (2.61%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epistaxis			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	2 / 115 (1.74%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea Exertional			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemothorax			
subjects affected / exposed	1 / 34 (2.94%)	0 / 34 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoxia			
subjects affected / exposed	0 / 34 (0.00%)	1 / 34 (2.94%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Pleural Effusion			
subjects affected / exposed	1 / 34 (2.94%)	1 / 34 (2.94%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	4 / 34 (11.76%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 4	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary Embolism			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary Toxicity			

subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory Distress			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	6 / 115 (5.22%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 7
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 2
Respiratory Failure			
subjects affected / exposed	3 / 34 (8.82%)	0 / 34 (0.00%)	5 / 115 (4.35%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 5
deaths causally related to treatment / all	0 / 3	0 / 0	0 / 5
Psychiatric disorders			
Agitation			
subjects affected / exposed	0 / 34 (0.00%)	1 / 34 (2.94%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anxiety			
subjects affected / exposed	0 / 34 (0.00%)	1 / 34 (2.94%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Confusional State			
subjects affected / exposed	0 / 34 (0.00%)	1 / 34 (2.94%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mental Status Changes			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Insomnia			
subjects affected / exposed	0 / 34 (0.00%)	1 / 34 (2.94%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			

Biopsy Bone Abnormal			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood Potassium Decreased			
subjects affected / exposed	0 / 34 (0.00%)	1 / 34 (2.94%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Brain Herniation			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Humerus Fracture			
subjects affected / exposed	0 / 34 (0.00%)	1 / 34 (2.94%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative Respiratory Distress			
subjects affected / exposed	1 / 34 (2.94%)	0 / 34 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Procedural Hypotension			
subjects affected / exposed	0 / 34 (0.00%)	1 / 34 (2.94%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rib Fracture			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Toxicity To Various Agents			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Wound Necrosis			
subjects affected / exposed	1 / 34 (2.94%)	0 / 34 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			
Aplasia			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Atrial Fibrillation			
subjects affected / exposed	0 / 34 (0.00%)	1 / 34 (2.94%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac Failure			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Cardio-Respiratory Arrest			
subjects affected / exposed	1 / 34 (2.94%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Tachycardia			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Altered State Of Consciousness			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coma			

subjects affected / exposed	0 / 34 (0.00%)	1 / 34 (2.94%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Convulsion			
subjects affected / exposed	1 / 34 (2.94%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encephalopathy			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	2 / 115 (1.74%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 2
Headache			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic Encephalopathy			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningeal Disorder			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nerve Compression			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myoclonus			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral Sensory Neuropathy			

subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal Cord Compression			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	2 / 115 (1.74%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Toxic Encephalopathy			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	3 / 115 (2.61%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile Neutropenia			
subjects affected / exposed	2 / 34 (5.88%)	0 / 34 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile Bone Marrow Aplasia			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			
subjects affected / exposed	0 / 34 (0.00%)	1 / 34 (2.94%)	4 / 115 (3.48%)
occurrences causally related to treatment / all	0 / 0	2 / 2	3 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			

Blindness Unilateral			
subjects affected / exposed	0 / 34 (0.00%)	1 / 34 (2.94%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vision Blurred			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal Pain			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	3 / 115 (2.61%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	2 / 115 (1.74%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal Pain			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileus			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper Gastrointestinal Haemorrhage			

subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retroperitoneal Haemorrhage			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	2 / 115 (1.74%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Hepatic Haemorrhage			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Jaundice			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Petechiae			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Nephrolithiasis			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Arthralgia			

subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	2 / 115 (1.74%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Back Pain			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	3 / 115 (2.61%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bursitis			
subjects affected / exposed	0 / 34 (0.00%)	1 / 34 (2.94%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Flank Pain			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal Pain			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypercreatinaemia			
subjects affected / exposed	0 / 34 (0.00%)	1 / 34 (2.94%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Appendicitis			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Central Nervous System Infection			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchopneumonia			

subjects affected / exposed	1 / 34 (2.94%)	0 / 34 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis Viral			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes Zoster			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Otitis Media			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	1 / 34 (2.94%)	0 / 34 (0.00%)	2 / 115 (1.74%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia Viral			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative Wound Infection			

subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post Procedural Infection			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary Tract Infection			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Decreased Appetite			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	2 / 115 (1.74%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	0 / 34 (0.00%)	1 / 34 (2.94%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Group 1: 10mg/kg		
Total subjects affected by serious adverse events			
subjects affected / exposed	8 / 33 (24.24%)		
number of deaths (all causes)	1		
number of deaths resulting from adverse events	0		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cancer Pain			

subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Malignant Pleural Effusion			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Osteosarcoma Recurrent			
subjects affected / exposed	1 / 33 (3.03%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Metastases To Lung			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Tumour Pain			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vascular disorders			
Hypotension			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Haemorrhage			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Shock Haemorrhagic			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Surgical and medical procedures			

Leg Amputation			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Medical Device Removal			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Wound Treatment			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Thoracotomy			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Chest Pain			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Device Dislocation			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Condition Aggravated			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Fatigue				
subjects affected / exposed	0 / 33 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Drug Withdrawal Syndrome				
subjects affected / exposed	0 / 33 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hyperthermia				
subjects affected / exposed	0 / 33 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
General Physical Health Deterioration				
subjects affected / exposed	0 / 33 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Influenza Like Illness				
subjects affected / exposed	0 / 33 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Malaise				
subjects affected / exposed	0 / 33 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Mucosal Inflammation				
subjects affected / exposed	0 / 33 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Multi-Organ Failure				
subjects affected / exposed	0 / 33 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Oedema Peripheral				

subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pain			
subjects affected / exposed	1 / 33 (3.03%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Performance Status Decreased			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pyrexia			
subjects affected / exposed	1 / 33 (3.03%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Acute respiratory distress syndrome			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Acute Respiratory Failure			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bronchial Disorder			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Dyspnoea At Rest			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Dyspnoea			

subjects affected / exposed	0 / 33 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Epistaxis				
subjects affected / exposed	0 / 33 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Dyspnoea Exertional				
subjects affected / exposed	0 / 33 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Haemothorax				
subjects affected / exposed	0 / 33 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hypoxia				
subjects affected / exposed	0 / 33 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pleural Effusion				
subjects affected / exposed	0 / 33 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pneumothorax				
subjects affected / exposed	1 / 33 (3.03%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Pulmonary Embolism				
subjects affected / exposed	0 / 33 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pulmonary Toxicity				

subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory Distress			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory Failure			
subjects affected / exposed	1 / 33 (3.03%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Psychiatric disorders			
Agitation			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Anxiety			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Confusional State			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Mental Status Changes			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Insomnia			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Investigations			

Biopsy Bone Abnormal subjects affected / exposed	1 / 33 (3.03%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Blood Potassium Decreased subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Brain Herniation subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Humerus Fracture subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Postoperative Respiratory Distress subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Procedural Hypotension subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Rib Fracture subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Toxicity To Various Agents subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Wound Necrosis			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Congenital, familial and genetic disorders			
Aplasia			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Atrial Fibrillation			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac Failure			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardio-Respiratory Arrest			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Tachycardia			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Altered State Of Consciousness			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Coma			

subjects affected / exposed	0 / 33 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Convulsion				
subjects affected / exposed	0 / 33 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Encephalopathy				
subjects affected / exposed	0 / 33 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Headache				
subjects affected / exposed	0 / 33 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hepatic Encephalopathy				
subjects affected / exposed	0 / 33 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Meningeal Disorder				
subjects affected / exposed	0 / 33 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Nerve Compression				
subjects affected / exposed	0 / 33 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Myoclonus				
subjects affected / exposed	0 / 33 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Peripheral Sensory Neuropathy				

subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Syncope			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Spinal Cord Compression			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Toxic Encephalopathy			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Febrile Neutropenia			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Febrile Bone Marrow Aplasia			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Thrombocytopenia			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Eye disorders			

Blindness Unilateral			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vision Blurred			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Abdominal Pain			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Constipation			
subjects affected / exposed	1 / 33 (3.03%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Diarrhoea			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal Pain			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ileus			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nausea			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Upper Gastrointestinal Haemorrhage			

subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Retroperitoneal Haemorrhage			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vomiting			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary disorders			
Hepatic Haemorrhage			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Jaundice			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Skin and subcutaneous tissue disorders			
Petechiae			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Nephrolithiasis			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Arthralgia			

subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Back Pain			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bursitis			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Flank Pain			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal Pain			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypercreatinaemia			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Appendicitis			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Central Nervous System Infection			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bronchopneumonia			

subjects affected / exposed	0 / 33 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastroenteritis				
subjects affected / exposed	0 / 33 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastroenteritis Viral				
subjects affected / exposed	0 / 33 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Herpes Zoster				
subjects affected / exposed	0 / 33 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Infection				
subjects affected / exposed	0 / 33 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Otitis Media				
subjects affected / exposed	0 / 33 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pneumonia				
subjects affected / exposed	0 / 33 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pneumonia Viral				
subjects affected / exposed	0 / 33 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Postoperative Wound Infection				

subjects affected / exposed	1 / 33 (3.03%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Post Procedural Infection			
subjects affected / exposed	1 / 33 (3.03%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Urinary Tract Infection			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Sepsis			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Decreased Appetite			
subjects affected / exposed	1 / 33 (3.03%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hyperglycaemia			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Group 1: 0.3mg/kg	Group 2: 10mg/kg	Group 3: 10mg/kg
Total subjects affected by non-serious adverse events			
subjects affected / exposed	28 / 34 (82.35%)	29 / 34 (85.29%)	104 / 115 (90.43%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Tumour Pain			
subjects affected / exposed	0 / 34 (0.00%)	2 / 34 (5.88%)	8 / 115 (6.96%)
occurrences (all)	0	2	11

Vascular disorders			
Hypotension			
subjects affected / exposed	2 / 34 (5.88%)	2 / 34 (5.88%)	6 / 115 (5.22%)
occurrences (all)	2	2	6
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 34 (0.00%)	1 / 34 (2.94%)	13 / 115 (11.30%)
occurrences (all)	0	1	18
Fatigue			
subjects affected / exposed	7 / 34 (20.59%)	7 / 34 (20.59%)	23 / 115 (20.00%)
occurrences (all)	10	7	28
Chest Pain			
subjects affected / exposed	7 / 34 (20.59%)	3 / 34 (8.82%)	10 / 115 (8.70%)
occurrences (all)	8	3	12
Mucosal Inflammation			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Oedema Peripheral			
subjects affected / exposed	2 / 34 (5.88%)	3 / 34 (8.82%)	4 / 115 (3.48%)
occurrences (all)	2	3	4
Pain			
subjects affected / exposed	4 / 34 (11.76%)	2 / 34 (5.88%)	9 / 115 (7.83%)
occurrences (all)	4	2	11
Pyrexia			
subjects affected / exposed	9 / 34 (26.47%)	6 / 34 (17.65%)	21 / 115 (18.26%)
occurrences (all)	11	7	37
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	10 / 34 (29.41%)	6 / 34 (17.65%)	16 / 115 (13.91%)
occurrences (all)	10	6	19
Dyspnoea			
subjects affected / exposed	6 / 34 (17.65%)	4 / 34 (11.76%)	7 / 115 (6.09%)
occurrences (all)	7	4	7
Dyspnoea Exertional			
subjects affected / exposed	4 / 34 (11.76%)	2 / 34 (5.88%)	11 / 115 (9.57%)
occurrences (all)	5	2	11

Epistaxis			
subjects affected / exposed	3 / 34 (8.82%)	0 / 34 (0.00%)	9 / 115 (7.83%)
occurrences (all)	6	0	11
Haemoptysis			
subjects affected / exposed	3 / 34 (8.82%)	2 / 34 (5.88%)	2 / 115 (1.74%)
occurrences (all)	3	3	3
Oropharyngeal Pain			
subjects affected / exposed	3 / 34 (8.82%)	2 / 34 (5.88%)	11 / 115 (9.57%)
occurrences (all)	4	2	15
Pleural Effusion			
subjects affected / exposed	3 / 34 (8.82%)	1 / 34 (2.94%)	6 / 115 (5.22%)
occurrences (all)	4	2	6
Pneumothorax			
subjects affected / exposed	4 / 34 (11.76%)	1 / 34 (2.94%)	2 / 115 (1.74%)
occurrences (all)	5	1	2
Wheezing			
subjects affected / exposed	3 / 34 (8.82%)	0 / 34 (0.00%)	3 / 115 (2.61%)
occurrences (all)	4	0	4
Rhinorrhoea			
subjects affected / exposed	1 / 34 (2.94%)	1 / 34 (2.94%)	1 / 115 (0.87%)
occurrences (all)	1	1	1
Psychiatric disorders			
Anxiety			
subjects affected / exposed	2 / 34 (5.88%)	3 / 34 (8.82%)	18 / 115 (15.65%)
occurrences (all)	2	3	24
Insomnia			
subjects affected / exposed	4 / 34 (11.76%)	2 / 34 (5.88%)	20 / 115 (17.39%)
occurrences (all)	4	2	20
Depression			
subjects affected / exposed	1 / 34 (2.94%)	2 / 34 (5.88%)	4 / 115 (3.48%)
occurrences (all)	1	2	4
Investigations			
Blood Alkaline Phosphatase Increased			
subjects affected / exposed	1 / 34 (2.94%)	1 / 34 (2.94%)	3 / 115 (2.61%)
occurrences (all)	1	1	3
Aspartate Aminotransferase Increased			

subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	8 / 115 (6.96%)
occurrences (all)	0	0	11
Gamma-Glutamyltransferase Increased			
subjects affected / exposed	0 / 34 (0.00%)	0 / 34 (0.00%)	9 / 115 (7.83%)
occurrences (all)	0	0	11
Haemoglobin Decreased			
subjects affected / exposed	5 / 34 (14.71%)	1 / 34 (2.94%)	3 / 115 (2.61%)
occurrences (all)	6	1	4
Platelet Count Decreased			
subjects affected / exposed	3 / 34 (8.82%)	0 / 34 (0.00%)	2 / 115 (1.74%)
occurrences (all)	4	0	6
Weight Decreased			
subjects affected / exposed	1 / 34 (2.94%)	2 / 34 (5.88%)	11 / 115 (9.57%)
occurrences (all)	1	2	13
Injury, poisoning and procedural complications			
Incision Site Pain			
subjects affected / exposed	1 / 34 (2.94%)	1 / 34 (2.94%)	2 / 115 (1.74%)
occurrences (all)	1	1	3
Procedural Pain			
subjects affected / exposed	13 / 34 (38.24%)	1 / 34 (2.94%)	2 / 115 (1.74%)
occurrences (all)	16	1	2
Post Procedural Haemorrhage			
subjects affected / exposed	2 / 34 (5.88%)	0 / 34 (0.00%)	0 / 115 (0.00%)
occurrences (all)	2	0	0
Post-Thoracotomy Pain Syndrome			
subjects affected / exposed	3 / 34 (8.82%)	1 / 34 (2.94%)	0 / 115 (0.00%)
occurrences (all)	3	1	0
Cardiac disorders			
Sinus Tachycardia			
subjects affected / exposed	2 / 34 (5.88%)	0 / 34 (0.00%)	0 / 115 (0.00%)
occurrences (all)	2	0	0
Tachycardia			
subjects affected / exposed	2 / 34 (5.88%)	1 / 34 (2.94%)	4 / 115 (3.48%)
occurrences (all)	2	1	4
Nervous system disorders			

Dizziness subjects affected / exposed occurrences (all)	1 / 34 (2.94%) 1	0 / 34 (0.00%) 0	7 / 115 (6.09%) 10
Headache subjects affected / exposed occurrences (all)	9 / 34 (26.47%) 16	7 / 34 (20.59%) 10	24 / 115 (20.87%) 57
Somnolence subjects affected / exposed occurrences (all)	1 / 34 (2.94%) 1	0 / 34 (0.00%) 0	7 / 115 (6.09%) 9
Blood and lymphatic system disorders			
Anaemia subjects affected / exposed occurrences (all)	6 / 34 (17.65%) 8	3 / 34 (8.82%) 4	22 / 115 (19.13%) 44
Thrombocytopenia subjects affected / exposed occurrences (all)	1 / 34 (2.94%) 2	1 / 34 (2.94%) 1	17 / 115 (14.78%) 35
Leukopenia subjects affected / exposed occurrences (all)	1 / 34 (2.94%) 1	0 / 34 (0.00%) 0	3 / 115 (2.61%) 4
Neutropenia subjects affected / exposed occurrences (all)	0 / 34 (0.00%) 0	0 / 34 (0.00%) 0	6 / 115 (5.22%) 6
Ear and labyrinth disorders			
Tinnitus subjects affected / exposed occurrences (all)	2 / 34 (5.88%) 2	0 / 34 (0.00%) 0	1 / 115 (0.87%) 1
Gastrointestinal disorders			
Abdominal Pain Upper subjects affected / exposed occurrences (all)	2 / 34 (5.88%) 2	1 / 34 (2.94%) 1	9 / 115 (7.83%) 10
Abdominal Pain subjects affected / exposed occurrences (all)	1 / 34 (2.94%) 1	0 / 34 (0.00%) 0	9 / 115 (7.83%) 13
Constipation subjects affected / exposed occurrences (all)	9 / 34 (26.47%) 9	3 / 34 (8.82%) 3	34 / 115 (29.57%) 43
Diarrhoea			

subjects affected / exposed	3 / 34 (8.82%)	2 / 34 (5.88%)	29 / 115 (25.22%)
occurrences (all)	6	2	42
Gastroesophageal Reflux Disease			
subjects affected / exposed	1 / 34 (2.94%)	0 / 34 (0.00%)	6 / 115 (5.22%)
occurrences (all)	1	0	6
Dyspepsia			
subjects affected / exposed	1 / 34 (2.94%)	2 / 34 (5.88%)	4 / 115 (3.48%)
occurrences (all)	1	2	5
Nausea			
subjects affected / exposed	13 / 34 (38.24%)	5 / 34 (14.71%)	35 / 115 (30.43%)
occurrences (all)	20	6	48
Vomiting			
subjects affected / exposed	9 / 34 (26.47%)	3 / 34 (8.82%)	25 / 115 (21.74%)
occurrences (all)	12	4	40
Stomatitis			
subjects affected / exposed	2 / 34 (5.88%)	0 / 34 (0.00%)	6 / 115 (5.22%)
occurrences (all)	2	0	6
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	1 / 34 (2.94%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences (all)	1	0	1
Pruritus			
subjects affected / exposed	6 / 34 (17.65%)	2 / 34 (5.88%)	5 / 115 (4.35%)
occurrences (all)	8	2	6
Rash			
subjects affected / exposed	3 / 34 (8.82%)	1 / 34 (2.94%)	11 / 115 (9.57%)
occurrences (all)	6	1	12
Urticaria			
subjects affected / exposed	3 / 34 (8.82%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences (all)	4	0	1
Subcutaneous Emphysema			
subjects affected / exposed	2 / 34 (5.88%)	0 / 34 (0.00%)	1 / 115 (0.87%)
occurrences (all)	2	0	1
Renal and urinary disorders			
Dysuria			

subjects affected / exposed	0 / 34 (0.00%)	3 / 34 (8.82%)	2 / 115 (1.74%)
occurrences (all)	0	3	3
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	4 / 34 (11.76%)	3 / 34 (8.82%)	10 / 115 (8.70%)
occurrences (all)	4	3	12
Bone Pain			
subjects affected / exposed	0 / 34 (0.00%)	4 / 34 (11.76%)	6 / 115 (5.22%)
occurrences (all)	0	4	6
Back Pain			
subjects affected / exposed	5 / 34 (14.71%)	6 / 34 (17.65%)	15 / 115 (13.04%)
occurrences (all)	5	7	19
Flank Pain			
subjects affected / exposed	1 / 34 (2.94%)	2 / 34 (5.88%)	2 / 115 (1.74%)
occurrences (all)	1	3	5
Muscle Spasms			
subjects affected / exposed	2 / 34 (5.88%)	2 / 34 (5.88%)	11 / 115 (9.57%)
occurrences (all)	3	2	13
Muscular Weakness			
subjects affected / exposed	0 / 34 (0.00%)	2 / 34 (5.88%)	3 / 115 (2.61%)
occurrences (all)	0	2	3
Myalgia			
subjects affected / exposed	1 / 34 (2.94%)	2 / 34 (5.88%)	6 / 115 (5.22%)
occurrences (all)	1	2	7
Musculoskeletal Chest Pain			
subjects affected / exposed	0 / 34 (0.00%)	4 / 34 (11.76%)	7 / 115 (6.09%)
occurrences (all)	0	4	8
Musculoskeletal Pain			
subjects affected / exposed	3 / 34 (8.82%)	1 / 34 (2.94%)	13 / 115 (11.30%)
occurrences (all)	3	1	16
Pain In Extremity			
subjects affected / exposed	7 / 34 (20.59%)	6 / 34 (17.65%)	12 / 115 (10.43%)
occurrences (all)	9	8	25
Neck Pain			

subjects affected / exposed occurrences (all)	0 / 34 (0.00%) 0	2 / 34 (5.88%) 2	6 / 115 (5.22%) 6
Pain In Jaw subjects affected / exposed occurrences (all)	2 / 34 (5.88%) 2	0 / 34 (0.00%) 0	2 / 115 (1.74%) 2
Infections and infestations			
Bronchitis subjects affected / exposed occurrences (all)	2 / 34 (5.88%) 2	1 / 34 (2.94%) 1	0 / 115 (0.00%) 0
Nasopharyngitis subjects affected / exposed occurrences (all)	1 / 34 (2.94%) 1	2 / 34 (5.88%) 2	1 / 115 (0.87%) 2
Sinusitis subjects affected / exposed occurrences (all)	2 / 34 (5.88%) 2	0 / 34 (0.00%) 0	5 / 115 (4.35%) 6
Rhinitis subjects affected / exposed occurrences (all)	2 / 34 (5.88%) 2	0 / 34 (0.00%) 0	2 / 115 (1.74%) 2
Urinary Tract Infection subjects affected / exposed occurrences (all)	1 / 34 (2.94%) 1	4 / 34 (11.76%) 4	8 / 115 (6.96%) 12
Upper Respiratory Tract Infection subjects affected / exposed occurrences (all)	7 / 34 (20.59%) 7	1 / 34 (2.94%) 1	7 / 115 (6.09%) 13
Metabolism and nutrition disorders			
Decreased Appetite subjects affected / exposed occurrences (all)	5 / 34 (14.71%) 6	4 / 34 (11.76%) 4	27 / 115 (23.48%) 37
Hyperglycaemia subjects affected / exposed occurrences (all)	6 / 34 (17.65%) 11	1 / 34 (2.94%) 1	12 / 115 (10.43%) 18
Dehydration subjects affected / exposed occurrences (all)	0 / 34 (0.00%) 0	1 / 34 (2.94%) 1	6 / 115 (5.22%) 6
Hypocalcaemia			

subjects affected / exposed	3 / 34 (8.82%)	2 / 34 (5.88%)	4 / 115 (3.48%)
occurrences (all)	6	2	8
Hypoalbuminaemia			
subjects affected / exposed	2 / 34 (5.88%)	0 / 34 (0.00%)	5 / 115 (4.35%)
occurrences (all)	2	0	5
Hypokalaemia			
subjects affected / exposed	3 / 34 (8.82%)	0 / 34 (0.00%)	6 / 115 (5.22%)
occurrences (all)	4	0	8
Hypophosphataemia			
subjects affected / exposed	1 / 34 (2.94%)	1 / 34 (2.94%)	2 / 115 (1.74%)
occurrences (all)	1	1	2
Hyponatraemia			
subjects affected / exposed	4 / 34 (11.76%)	1 / 34 (2.94%)	2 / 115 (1.74%)
occurrences (all)	5	1	2

Non-serious adverse events	Group 1: 10mg/kg		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	30 / 33 (90.91%)		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Tumour Pain			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences (all)	0		
Vascular disorders			
Hypotension			
subjects affected / exposed	1 / 33 (3.03%)		
occurrences (all)	1		
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	1 / 33 (3.03%)		
occurrences (all)	4		
Fatigue			
subjects affected / exposed	7 / 33 (21.21%)		
occurrences (all)	8		
Chest Pain			
subjects affected / exposed	3 / 33 (9.09%)		
occurrences (all)	3		

Mucosal Inflammation subjects affected / exposed occurrences (all)	2 / 33 (6.06%) 7		
Oedema Peripheral subjects affected / exposed occurrences (all)	2 / 33 (6.06%) 2		
Pain subjects affected / exposed occurrences (all)	4 / 33 (12.12%) 4		
Pyrexia subjects affected / exposed occurrences (all)	11 / 33 (33.33%) 13		
Respiratory, thoracic and mediastinal disorders			
Cough subjects affected / exposed occurrences (all)	7 / 33 (21.21%) 9		
Dyspnoea subjects affected / exposed occurrences (all)	4 / 33 (12.12%) 4		
Dyspnoea Exertional subjects affected / exposed occurrences (all)	2 / 33 (6.06%) 2		
Epistaxis subjects affected / exposed occurrences (all)	2 / 33 (6.06%) 5		
Haemoptysis subjects affected / exposed occurrences (all)	2 / 33 (6.06%) 2		
Oropharyngeal Pain subjects affected / exposed occurrences (all)	1 / 33 (3.03%) 1		
Pleural Effusion subjects affected / exposed occurrences (all)	1 / 33 (3.03%) 1		
Pneumothorax			

subjects affected / exposed occurrences (all)	2 / 33 (6.06%) 3		
Wheezing subjects affected / exposed occurrences (all)	0 / 33 (0.00%) 0		
Rhinorrhoea subjects affected / exposed occurrences (all)	5 / 33 (15.15%) 10		
Psychiatric disorders			
Anxiety subjects affected / exposed occurrences (all)	3 / 33 (9.09%) 3		
Insomnia subjects affected / exposed occurrences (all)	3 / 33 (9.09%) 4		
Depression subjects affected / exposed occurrences (all)	3 / 33 (9.09%) 4		
Investigations			
Blood Alkaline Phosphatase Increased subjects affected / exposed occurrences (all)	2 / 33 (6.06%) 2		
Aspartate Aminotransferase Increased subjects affected / exposed occurrences (all)	0 / 33 (0.00%) 0		
Gamma-Glutamyltransferase Increased subjects affected / exposed occurrences (all)	1 / 33 (3.03%) 1		
Haemoglobin Decreased subjects affected / exposed occurrences (all)	6 / 33 (18.18%) 12		
Platelet Count Decreased subjects affected / exposed occurrences (all)	1 / 33 (3.03%) 1		
Weight Decreased			

subjects affected / exposed occurrences (all)	1 / 33 (3.03%) 1		
Injury, poisoning and procedural complications			
Incision Site Pain			
subjects affected / exposed	2 / 33 (6.06%)		
occurrences (all)	2		
Procedural Pain			
subjects affected / exposed	6 / 33 (18.18%)		
occurrences (all)	7		
Post Procedural Haemorrhage			
subjects affected / exposed	1 / 33 (3.03%)		
occurrences (all)	1		
Post-Thoracotomy Pain Syndrome			
subjects affected / exposed	1 / 33 (3.03%)		
occurrences (all)	1		
Cardiac disorders			
Sinus Tachycardia			
subjects affected / exposed	1 / 33 (3.03%)		
occurrences (all)	1		
Tachycardia			
subjects affected / exposed	1 / 33 (3.03%)		
occurrences (all)	1		
Nervous system disorders			
Dizziness			
subjects affected / exposed	1 / 33 (3.03%)		
occurrences (all)	1		
Headache			
subjects affected / exposed	7 / 33 (21.21%)		
occurrences (all)	8		
Somnolence			
subjects affected / exposed	1 / 33 (3.03%)		
occurrences (all)	1		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	2 / 33 (6.06%)		
occurrences (all)	3		

Thrombocytopenia subjects affected / exposed occurrences (all)	0 / 33 (0.00%) 0		
Leukopenia subjects affected / exposed occurrences (all)	2 / 33 (6.06%) 2		
Neutropenia subjects affected / exposed occurrences (all)	1 / 33 (3.03%) 1		
Ear and labyrinth disorders Tinnitus subjects affected / exposed occurrences (all)	3 / 33 (9.09%) 3		
Gastrointestinal disorders Abdominal Pain Upper subjects affected / exposed occurrences (all)	0 / 33 (0.00%) 0		
Abdominal Pain subjects affected / exposed occurrences (all)	3 / 33 (9.09%) 3		
Constipation subjects affected / exposed occurrences (all)	9 / 33 (27.27%) 10		
Diarrhoea subjects affected / exposed occurrences (all)	6 / 33 (18.18%) 11		
Gastrooesophageal Reflux Disease subjects affected / exposed occurrences (all)	0 / 33 (0.00%) 0		
Dyspepsia subjects affected / exposed occurrences (all)	1 / 33 (3.03%) 2		
Nausea subjects affected / exposed occurrences (all)	12 / 33 (36.36%) 18		
Vomiting			

subjects affected / exposed	8 / 33 (24.24%)		
occurrences (all)	9		
Stomatitis			
subjects affected / exposed	1 / 33 (3.03%)		
occurrences (all)	1		
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	2 / 33 (6.06%)		
occurrences (all)	2		
Pruritus			
subjects affected / exposed	4 / 33 (12.12%)		
occurrences (all)	6		
Rash			
subjects affected / exposed	2 / 33 (6.06%)		
occurrences (all)	2		
Urticaria			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences (all)	0		
Subcutaneous Emphysema			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences (all)	0		
Renal and urinary disorders			
Dysuria			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences (all)	0		
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	2 / 33 (6.06%)		
occurrences (all)	4		
Bone Pain			
subjects affected / exposed	1 / 33 (3.03%)		
occurrences (all)	1		
Back Pain			
subjects affected / exposed	4 / 33 (12.12%)		
occurrences (all)	4		
Flank Pain			

subjects affected / exposed	0 / 33 (0.00%)		
occurrences (all)	0		
Muscle Spasms			
subjects affected / exposed	3 / 33 (9.09%)		
occurrences (all)	6		
Muscular Weakness			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences (all)	0		
Myalgia			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences (all)	0		
Musculoskeletal Chest Pain			
subjects affected / exposed	2 / 33 (6.06%)		
occurrences (all)	2		
Musculoskeletal Pain			
subjects affected / exposed	2 / 33 (6.06%)		
occurrences (all)	2		
Pain In Extremity			
subjects affected / exposed	4 / 33 (12.12%)		
occurrences (all)	8		
Neck Pain			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences (all)	0		
Pain In Jaw			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences (all)	0		
Infections and infestations			
Bronchitis			
subjects affected / exposed	1 / 33 (3.03%)		
occurrences (all)	1		
Nasopharyngitis			
subjects affected / exposed	2 / 33 (6.06%)		
occurrences (all)	2		
Sinusitis			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences (all)	0		

Rhinitis			
subjects affected / exposed	1 / 33 (3.03%)		
occurrences (all)	1		
Urinary Tract Infection			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences (all)	0		
Upper Respiratory Tract Infection			
subjects affected / exposed	3 / 33 (9.09%)		
occurrences (all)	4		
Metabolism and nutrition disorders			
Decreased Appetite			
subjects affected / exposed	4 / 33 (12.12%)		
occurrences (all)	5		
Hyperglycaemia			
subjects affected / exposed	3 / 33 (9.09%)		
occurrences (all)	6		
Dehydration			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences (all)	0		
Hypocalcaemia			
subjects affected / exposed	0 / 33 (0.00%)		
occurrences (all)	0		
Hypoalbuminaemia			
subjects affected / exposed	3 / 33 (9.09%)		
occurrences (all)	3		
Hypokalaemia			
subjects affected / exposed	2 / 33 (6.06%)		
occurrences (all)	3		
Hypophosphataemia			
subjects affected / exposed	2 / 33 (6.06%)		
occurrences (all)	2		
Hyponatraemia			
subjects affected / exposed	2 / 33 (6.06%)		
occurrences (all)	2		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
06 May 2008	AM1: Inclusion criteria were modified to permit a wider selection of previous chemotherapy regimens for Groups 1 and 2. Study objectives were modified and overall survival for all groups added. For subjects relapsing after treatment with SCH 717454 at 0.3 mg/kg IV not eligible for surgical resection, consideration for treatment with 10 mg/kg IV was to be discussed with the Sponsor.
01 August 2008	AM2: Response criteria were modified because of characteristics of osteosarcoma tumors (significant matrix); participants with disease after resection could remain on study treatment; observation of participants post-treatment could be adjusted for state and local regulations.
01 May 2009	AM3: Allowed younger participants to be enrolled.
08 December 2010	AM4: Changes to vial fill and drug supply.
14 September 2011	AM5: The primary reason for amendment is to discontinue protocol-specific procedures that fall outside of the standard-of-care and to stop data collection except for SAE reports.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

The study was stopped prematurely for administrative reasons; not all planned endpoints were analyzed.

Notes: